Zimmer Biomet Holdings Inc (ZBH)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $19.53B
Last updated: Nov 17, 2026 at 4:34 PM ET
Zimmer Biomet Holdings Inc (ZBH) Statistics
Zimmer Biomet Holdings (ZBH) has a market cap of $19.53B and an enterprise value of $26.64B. Its share count is down 3.84% from a year earlier. Its return on invested capital of 5.04% compares with a 11.05% median across 8 similar companies.
Total Valuation
Enterprise value is 36.37% above the market cap, as debt exceeds cash.
| Market Cap | $19.53B |
|---|---|
| Enterprise Value | $26.64B |
| Latest price (Nov 17, 2026) | $102.11 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Sep 30, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Last Ex-Dividend Date | Sep 30, 2026 |
| Last Payment Date | Oct 30, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.3x and 1.5x. Its year-end P/E ranged from 11.0x to 27.2x from 2016 to 2025.
| P/E Ratio | 12.0x |
|---|---|
| Forward P/E | 11.8x |
| P/S Ratio | 2.3x |
| Forward P/S | 2.3x |
| P/B Ratio | 1.5x |
| P/FCF Ratio | 11.8x |
| P/OCF Ratio | 10.4x |
| PEG Ratio | 2.1 |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.6x EBITDA and 16.2x free cash flow.
| EV / Earnings | 34.7x |
|---|---|
| EV / Sales | 3.1x |
| EV / EBITDA | 11.6x |
| EV / EBIT | 22.7x |
| EV / FCF | 16.2x |
Price Statistics
The stock is up 14.47% over 52 weeks and trades 6.45% above its 50-day average.
| Beta (1Y) | 0.43 |
|---|---|
| 52-Week Change | +14.47% |
| 1-Month Change | +7.50% |
| 3-Month Change | +1.63% |
| 6-Month Change | +19.26% |
| 5-Year Change | -33.96% |
| 10-Year Change | -10.32% |
| Total Return (1Y) | +15.55% |
| Total Return (3Y CAGR) | -2.11% |
| Total Return (5Y CAGR) | -3.19% |
| Return vs SPY (1Y) | +3.98% |
| Max Drawdown (1Y) | -21.20% |
| Max Drawdown (3Y) | -38.99% |
| Sharpe Ratio (1Y) | 0.45 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $95.92 |
| 200-Day Average | $92.39 |
| 52-Week Range | $78.70 to $112.55 |
| RSI (14 Days) | 53.6 |
| Average Volume (20 Days) | 2.62M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.46x current liabilities, and total debt is 0.59x shareholder equity.
| Current Ratio | 1.46x |
|---|---|
| Quick Ratio | 0.79x |
| Debt / Equity | 0.59x |
| Debt / EBITDA | 3.29x |
| Debt / FCF | 4.57x |
| Interest Coverage | 4.07x |
Returns and Efficiency
Return on invested capital is 5.04% over the last 12 months, against a 5-year average of 4.70%.
| Return on Equity (ROE) | 6.04% |
|---|---|
| Return on Assets (ROA) | 3.26% |
| Return on Invested Capital (ROIC) | 5.04% |
| Return on Capital Employed (ROCE) | 5.86% |
| ROE (5Y Average) | 5.22% |
| ROA (5Y Average) | 2.97% |
| ROIC (5Y Average) | 4.70% |
| Asset Turnover | 0.36x |
| Inventory Turnover | 1.12x |
| Receivables Turnover | 4.78x |
| Cash Conversion Cycle | 352 days |
Taxes
Income tax took 13.08% of pretax income over the last 12 months.
| Income Tax (TTM) | $115.70M |
|---|---|
| Effective Tax Rate | 13.08% |
Scores
ZBH has an Altman Z-Score of 2.41, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.41 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $8.57B over the last 12 months is up 6.98% from the 12 months before.
| Revenue | $8.57B |
|---|---|
| Revenue Growth (YoY) | +6.98% |
| Gross Profit | $5.97B |
| Operating Income | $1.16B |
| Pretax Income | $884.50M |
| Net Income | $767.40M |
| EBITDA | $2.28B |
| EBIT | $1.17B |
| Reported EPS (TTM) | $8.48 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 54.04% of the $23.54B in total assets.
| Cash and Equivalents | $399.90M |
|---|---|
| Total Debt | $7.50B |
| Net Debt | $7.10B |
| Net Debt Per Share | $37.29 |
| Working Capital | $1.63B |
| Shareholder Equity | $12.72B |
| Book Value Per Share | $66.75 |
| Tangible Book Value | -$2.25B |
| Total Assets | $23.54B |
| Total Liabilities | $10.81B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $241.10M of capital spending, operating cash flow left $1.64B of free cash flow.
| Operating Cash Flow | $1.88B |
|---|---|
| Capital Expenditures | $241.10M |
| Free Cash Flow | $1.64B |
| FCF Per Share | $8.62 |
| Depreciation and Amortization | $1.11B |
| Dividends Paid | $186.70M |
| Share Repurchases | $829.30M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 13.55%, against a 5-year average of 14.00%.
| Gross Margin | 69.68% |
|---|---|
| Operating Margin | 13.55% |
| Pretax Margin | 10.32% |
| Net Margin | 8.95% |
| EBITDA Margin | 26.60% |
| EBIT Margin | 13.69% |
| FCF Margin | 19.18% |
| Gross Margin (5Y Average) | 71.03% |
| Operating Margin (5Y Average) | 14.00% |
| Net Margin (5Y Average) | 8.68% |
Growth
Revenue grew 5.85% a year over 3 years, and EPS 5.97% a year.
| Revenue Growth (3Y CAGR) | +5.85% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.08% |
| EPS Growth (3Y CAGR) | +5.97% |
| EPS Growth (5Y CAGR) | +7.66% |
| FCF Growth (3Y CAGR) | +8.02% |
| FCF Growth (5Y CAGR) | +8.85% |
| Operating Income Growth (3Y CAGR) | +16.40% |
| Book Value Per Share Growth (2Y CAGR) | +3.51% |
Dividends and Yields
ZBH pays out 9.70% of earnings as dividends.
| Dividend Per Share (Annual) | $0.96 |
|---|---|
| Dividend Yield | 0.94% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | 0.00% |
| Dividend Growth (5Y CAGR) | 0.00% |
| Payout Ratio | 9.70% |
| FCF Payout Ratio | 11.36% |
| Earnings Yield | 8.33% |
| FCF Yield | 8.45% |
| Buyback Yield | 4.12% |
| Shareholder Yield | 5.08% |
Peer Position
Against 9 similar companies, ZBH has the 9th highest P/E.
P/E RatioPeer median 22.0x
P/S RatioPeer median 3.0x
ROICPeer median 11.05%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.50%
Dividend YieldPeer median 0.00%
| P/E Ratio | 12.0x vs 22.0x median |
|---|---|
| P/S Ratio | 2.3x vs 3.0x median |
| ROIC | 5.04% vs 11.05% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.98% vs +8.50% median |
| Dividend Yield | 0.94% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.97% and EPS growth at 4.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.97% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +4.61% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ZBH
What is ZBH's market cap?
Zimmer Biomet Holdings has a market cap of $19.53B. Its enterprise value, which adds debt and subtracts cash, is $26.64B.
What is ZBH's P/E ratio?
Zimmer Biomet Holdings has a trailing P/E ratio of 12.0x and a forward P/E of 11.8x.
How many shares of ZBH are outstanding?
Zimmer Biomet Holdings has 190.50M shares outstanding. The count is down 3.84% from a year earlier.
Does ZBH pay a dividend?
Yes. Zimmer Biomet Holdings pays $0.96 a share a year, a dividend yield of 0.94%.
How much debt does ZBH have?
Zimmer Biomet Holdings has $7.50B of total debt and $399.90M of cash and equivalents, a net debt position of $7.10B.
ZBH pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts